Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

5,419 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II study of daily carboplatin plus irradiation followed by durvalumab therapy for older adults (≥75 years) with unresectable III non-small-cell lung cancer and performance status of 2: NEJ039A.
Mouri A, Kisohara A, Morita R, Ko R, Nakagawa T, Makiguchi T, Isobe K, Ishikawa N, Kondo T, Akiyama M, Bessho A, Honda R, Yoshimura K, Kagamu H, Kato S, Kobayashi K, Kaira K, Maemondo M. Mouri A, et al. Among authors: nakagawa t. ESMO Open. 2024 Oct;9(10):103939. doi: 10.1016/j.esmoop.2024.103939. Epub 2024 Oct 11. ESMO Open. 2024. PMID: 39395258 Free PMC article. Clinical Trial.
A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016).
Miura S, Maemondo M, Iwashima A, Harada T, Sugawara S, Kobayashi K, Inoue A, Nakagawa T, Takiguchi Y, Watanabe H, Ishida T, Terada M, Kagamu H, Gemma A, Yoshizawa H. Miura S, et al. Among authors: nakagawa t. Invest New Drugs. 2017 Apr;35(2):227-234. doi: 10.1007/s10637-017-0436-1. Epub 2017 Feb 1. Invest New Drugs. 2017. PMID: 28150074 Clinical Trial.
Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B).
Tsubata Y, Watanabe K, Saito R, Nakamura A, Yoshioka H, Morita M, Honda R, Kanaji N, Ohizumi S, Jingu D, Nakagawa T, Nakazawa K, Mouri A, Takeuchi S, Furuya N, Akazawa Y, Miura K, Ichihara E, Maemondo M, Morita S, Kobayashi K, Isobe T. Tsubata Y, et al. Among authors: nakagawa t. Int J Clin Oncol. 2022 Jan;27(1):112-120. doi: 10.1007/s10147-021-02043-2. Epub 2021 Oct 13. Int J Clin Oncol. 2022. PMID: 34643820 Free PMC article. Clinical Trial.
Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospective study (NEJ047).
Asao T, Shukuya T, Uemura K, Kitadai R, Yamamoto G, Mouri A, Tamaoka M, Imai R, Tsukita Y, Isobe K, Watanabe S, Kamimura M, Morita R, Kudo K, Inomata M, Tateishi K, Kakinuma K, Yoshioka H, Namba Y, Sumiyoshi I, Nakagawa T, Watanabe K, Kobayashi K, Takahashi K. Asao T, et al. Among authors: nakagawa t. Lung Cancer. 2024 Aug;194:107894. doi: 10.1016/j.lungcan.2024.107894. Epub 2024 Jul 14. Lung Cancer. 2024. PMID: 39029359
Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301.
Miyauchi E, Inoue A, Usui K, Sugawara S, Maemondo M, Saito H, Fujita Y, Kato T, Suzuki T, Harada T, Watanabe H, Nakagawa T, Ichinose M. Miyauchi E, et al. Among authors: nakagawa t. Oncologist. 2017 Jun;22(6):640-e59. doi: 10.1634/theoncologist.2017-0059. Epub 2017 May 19. Oncologist. 2017. PMID: 28526722 Free PMC article. Clinical Trial.
Randomized phase II trial of uracil/tegafur and cisplatin versus pemetrexed and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-squamous non-small cell lung cancer: NJLCG1001.
Watanabe K, Toi Y, Nakamura A, Chiba R, Akiyama M, Sakakibara-Konishi J, Tanaka H, Yoshimura N, Miyauchi E, Nakagawa T, Igusa R, Minemura H, Mori Y, Fujimoto K, Matsushita H, Takahashi F, Fukuhara T, Inoue A, Sugawara S, Maemondo M; North Japan Lung Cancer Study Group, Sendai, Japan. Watanabe K, et al. Among authors: nakagawa t. Transl Lung Cancer Res. 2021 Feb;10(2):712-722. doi: 10.21037/tlcr-20-721. Transl Lung Cancer Res. 2021. PMID: 33718016 Free PMC article.
Correction to: Osimertinib in poor performance status patients with T790M‑positive advanced non‑small‑cell lung cancer after progression of first- and second‑generation EGFR‑TKI treatments (NEJ032B).
Tsubata Y, Watanabe K, Saito R, Nakamura A, Yoshioka H, Morita M, Honda R, Kanaji N, Oizumi S, Jingu D, Nakagawa T, Nakazawa K, Mouri A, Takeuchi S, Furuya N, Akazawa Y, Miura K, Ichihara E, Maemondo M, Morita S, Kobayashi K, Isobe T. Tsubata Y, et al. Among authors: nakagawa t. Int J Clin Oncol. 2022 Apr;27(4):823-824. doi: 10.1007/s10147-022-02118-8. Int J Clin Oncol. 2022. PMID: 35257278 Free PMC article. No abstract available.
Real-world outcomes of chemotherapy for lung cancer patients undergoing hemodialysis: A multicenter retrospective cohort study (NEJ-042).
Minegishi Y, Akagami T, Arai M, Saito R, Arai D, Murase K, Miura K, Watanabe S, Sakashita H, Miyabayashi T, Honda R, Jingu D, Hotta T, Isobe K, Nakazawa K, Ito K, Takamura K, Inomata M, Harada T, Sakakibara R, Nakagawa T, Shibuya H, Takenaka K, Kobayashi K, Seike M. Minegishi Y, et al. Among authors: nakagawa t. Lung Cancer. 2022 Oct;172:1-8. doi: 10.1016/j.lungcan.2022.07.009. Epub 2022 Jul 26. Lung Cancer. 2022. PMID: 35952438 Review.
Extended ICI treatment after first-line chemoimmunotherapy could predict the clinical benefit of ramucirumab plus docetaxel in advanced non-small lung cancer: Post hoc analysis from NEJ051 (REACTIVE study).
Yamaguchi O, Mori K, Takata S, Shibata K, Chikamori K, Kimura N, Nagai Y, Nakagawa T, Igawa S, Harada T, Yoshioka H, Tanaka H, Nogawa H, Satoh H, Shiozawa T, Tsuji K, Kobayashi K, Kaira K. Yamaguchi O, et al. Among authors: nakagawa t. Thorac Cancer. 2024 Jan;15(2):163-171. doi: 10.1111/1759-7714.15173. Epub 2023 Nov 27. Thorac Cancer. 2024. PMID: 38013668 Free PMC article.
5,419 results